AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Senzime AB (publ)
Video analysis: SNZZF
All videosNo video analysis for this stock yet. Request one from our team.
News: SNZZF
Senzime Awarded Exclusive 5-Year National Supply Contract with U.S. Veterans Affairs Through Its Partner TrillaMed
UPPSALA, SE / ACCESS Newswire / August 5, 2026 / Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF), a leader in precision-based perioperative monitoring solutions, today announced that the U.S. Department of Veterans Affairs (VA) Strategic Acquisition Center has awarded a five-year national Non-Expendable Equipment (NX EQ) contract for quantitative neuromuscular monitoring to TrillaMed, LLC, the authorized U.S. federal distributor of the Senzime TetraGraph® system. The contract follows a competitive national procurement process and establishes TetraGraph as the only quantitative neuromuscular monitoring solution currently available through the VA Strategic Acquisition Center's national contracting program.
Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Transcript
Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Transcript
Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Prepared Remarks Transcript
Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Prepared Remarks Transcript
Interim Report Q2 2026: Strong Sensor Sales and Improved Margins, Despite Continued U.S. Monitor Market Headwinds
UPPSALA, SE / ACCESS Newswire / July 16, 2026 / Senzime AB's (publ) (STO:SEZI)(OTCQX:SNZZF) interim report for April - June (Q2) 2026 is now available on the company's website www.senzime.com. Financial information Q2 2026: Net sales amounted to TSEK 24,671 (25,695), a decrease of 4% Currency-adjusted net sales decreased by 1% Sales in the US amounted to TSEK 18,716 (19,930), a decrease of 6% Sales in the International markets amounted to TSEK 5,955 (5,765), an increase of 3% Gross margin before depreciation amounted to 65.7% (61.8) Operating costs amounted to TSEK 34,201 (40,207) Operating profit before depreciation amounted to TSEK -17,267 (-23,573) Results after financial items amounted to TSEK -21,385 (-34,159) Earnings per share amounted to SEK -0.14 (-0.24) Cash and cash equivalents as of June 30th amounted to TSEK 37,112 (132,162) Financial information first half of 2026: Net sales amounted to TSEK 47,904 (49,195), a decrease of 3% Currency-adjusted net sales increased by 4% Sales in the US amounted to TSEK 33,591 (35,481), a decrease of 6% Sales in the International markets amounted to TSEK 14,383 (13,714), an increase of 5% Gross margin before depreciation amounted to 64.4% (63.8) Operating costs amounted to TSEK 69,763 (77,504) Operating profit before depreciation amounted to TSEK -37,469 (-44,411) Results after financial items amounted to TSEK -44,627 (-69,981) Earnings per share amounted to SEK -0.28 (-0.50) Philip Siberg, CEO, comments: Sensor sales continued their strong momentum, driven by expanding utilization of TetraGraph systems in the market.
Senzime and Philips Medical Systems Enter Development and Commercialization Partnership
UPPSALA, SE / ACCESS Newswire / July 15, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB announced today that it has entered into a long-term agreement with Philips Electronics Nederland, B.V. through Philips Hospital Patient Monitoring business, a global leader in patient monitoring systems.
Invitation to Presentations of Senzime's Second Quarter 2026 Report
UPPSALA, SE / ACCESS Newswire / July 13, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) invites investors, analysts, and media to presentations of the second quarter report for 2026 on July 16. The report will be published at 08:00 am CEST the same day.
Senzime's TetraGraph System Receives ANVISA Regulatory Approval in Brazil
UPPSALA, SE / ACCESS Newswire / June 29, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) announced today that the TetraGraph system has received approval from the Brazilian Health Regulatory Agency (ANVISA), enabling sales in the Brazilian market. Senzime has initiated commercialization through a local partner, and first order has been received.
